Functional genomic analysis of glioblastoma multiforme through short interfering RNA screening: A paradigm for therapeutic development

Neurosurgical Focus

Volumn 28, Issue 1, 2010, Pages

  Thaker, Nikhil G ^a   Zhang, Fang ^b,c   McDonald, Peter R ^b,c   Shun, Tong Ying ^b,c   Lazo, John S ^b,c   Pollack, Ian F ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Genome wide screening; Glioblastoma multiforme; Protein protein interaction network; RNAi; Short interfering RNA

Indexed keywords

SMALL INTERFERING RNA;

ARTICLE; BIOLOGICAL MODEL; BRAIN TUMOR; CELL DEATH; CELL SURVIVAL; DRUG DEVELOPMENT; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENETICS; GENOMICS; GLIOBLASTOMA; HUMAN; METHODOLOGY; PHARMACOGENETICS; PROTEIN ANALYSIS; PROTEOMICS; TUMOR CELL LINE;

BRAIN NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DISCOVERY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; GLIOBLASTOMA; HUMANS; MODELS, GENETIC; PHARMACOGENETICS; PROTEIN INTERACTION MAPPING; PROTEOMICS; RNA, SMALL INTERFERING;

EID: 76549092868     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2009.10.FOCUS09210     Document Type: Review

References (77)

1. Anonymous: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068, 2008.
2. Apic G, Ignjatovic T, Boyer S, Russell RB: Illuminating drug discovery with biological pathways. FEBS Lett 579:1872-1877, 2005.
3. Bachi A, Bonaldi T: Quantitative proteomics as a new piece of the systems biology puzzle. J Proteomics 71:357-367, 2008.
4. Bartz S, Jackson AL: How will RNAi facilitate drug development? Sci STKE 295:pe39, 2005.
5. Borawski J, Lindeman A, Buxton F, Labow M, Gaither LA: Optimization procedure for small interfering RNA transfection in a 384-well format. J Biomol Screen 12:546-559, 2007.
6. Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, et al: Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 65:8679-8689, 2005.
7. Brideau C, Gunter B, Pikounis B, Liaw A: Improved statistical methods for hit selection in high-throughput screening. J Biomol Screen 8:634-647, 2003.
8. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917, 2005.
9. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, et al: A network-based analysis of systemic inflammation in humans. Nature 437:1032-1037, 2005.
10. Chung N, Zhang XD, Kreamer A, Locco L, Kuan PF, Bartz S, et al: Median absolute deviation to improve hit selection for genome-scale RNAi screens. J Biomol Screen 13:149-158, 2008.
11. Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K, et al: A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci U S A 103:3775-3780, 2006.
12. Coma I, Herranz J, Martin J: Statistics and decision making in high-throughput screening. Methods Mol Biol 565:69-106, 2009.
13. Daraselia N, Yuryev A, Egorov S, Mazo I, Ispolatov I: Automatic extraction of gene ontology annotation and its correlation with clusters in protein networks. BMC Bioinformatics 8:243, 2007.
14. Dezso Z, Nikolsky Y, Nikolskaya T, Miller J, Cherba D, Webb C, et al: Identifying disease-specific genes based on their topological significance in protein networks. BMC Syst Biol 3:36, 2009.
15. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921, 2005.
16. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134, 2009.
17. Fuchs F, Boutros M: Cellular phenotyping by RNAi. Brief Funct Genomics Proteomics 5:52-56, 2006.
18. Ganesan AK, Ho H, Bodemann B, Petersen S, Aruri J, Koshy S, et al: Genome-wide siRNA-based functional genomics of pigmentation identifies novel genes and pathways that impact melanogenesis in human cells. PLoS Genet 4:e1000298, 2008.
19. Giroux V, Iovanna J, Dagorn JC: Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. FASEB J 20:1982-1991, 2006.
20. Gobeil S, Zhu X, Doillon CJ, Green MR: A genome-wide shRNA screen identifies GAS1 as a novel melanoma metastasis suppressor gene. Genes Dev 22:2932-2940, 2008.
21. Gusev Y: Computational methods for analysis of cellular functions and pathways collectively targeted by differentially expressed microRNA. Methods 44:61-72, 2008.
22. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000.
23. Hawkins D: Identification of Outliers. London: Chapman and Hall, 1980.
24. Hopkins AL, Groom CR: The druggable genome. Nat Rev Drug Discov 1:727-730, 2002.
25. Horvath S, Zhang B, Carlson M, Lu KV, Zhu S, Felciano RM, et al: Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci U S A 103:17402-17407, 2006.
26. Hu G, Kim J, Xu Q, Leng Y, Orkin SH, Elledge SJ: A genomewide RNAi screen identifies a new transcriptional module required for self-renewal. Genes Dev 23:837-848, 2009.
27. Huang DW, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44-57, 2008.
28. Iglehart JD, Silver DP: Synthetic lethality-a new direction in cancer-drug development. N Engl J Med 361:189-191, 2009.
29. Iglewicz B, Hoaglin D: How to detect and handle outliers, in ASQC Basic References in Quality Control: Statistical Techniques. Milwaukee, WI: ASQC Quality Press, 1993, Vol 16.
30. Iorns E, Lord CJ, Turner N, Ashworth A: Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 6:556-568, 2007.
31. Kaelin WG Jr: The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5:689-698, 2005.
32. Kanehisa M: The KEGG database. Novartis Found Symp 247: 91-103, 119-128, 244-252, 2002.
33. Kittler R, Buchholz F: Functional genomic analysis of cell division by endoribonuclease-prepared siRNAs. Cell Cycle 4:564-567, 2005.
34. Kuwahara T, Koyama A, Koyama S, Yoshina S, Ren CH, Kato T, et al: A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in alpha-synuclein transgenic C. elegans. Hum Mol Genet 17:2997-3009, 2008.
35. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al: The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929-1935, 2006.
36. Leal JF, Ferrer I, Blanco-Aparicio C, Hernández-Losa J, Ramón Y Cajal S, Carnero A, et al: S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis. Carcinogenesis 29:2089-2095, 2008.
37. Lents NH, Baldassare JJ: RNA interference takes flight: a new RNAi screen reveals cell cycle regulators in Drosophila cells. Trends Endocrinol Metab 17:173-174, 2006.
38. Loh SHY, Francescut L, Lingor P, Bähr M, Nicotera P: Identification of new kinase clusters required for neurite outgrowth and retraction by a loss-of-function RNA interference screen. Cell Death Differ 15:283-298, 2008.
39. Lu PY, Xie FY, Woodle MC: Modulation of angiogenesis with siRNA inhibitors for novel therapeutics. Trends Mol Med 11:104-113, 2005.
40. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, et al: A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the ras oncogene. Cell 137:835-848, 2009.
41. Ma C, Mandrekar SJ, Alberts SR, Croghan GA, Jatoi A, Reid JM, et al: A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother Pharmacol 59: 207-215, 2007.
42. MacKeigan JP, Murphy LO, Blenis J: Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 7:591-600, 2005.
43. Martinez J, Patkaniowska A, Urlaub H, Lührmann R, Tuschl T: Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110:563-574, 2002.
44. Mi H, Guo N, Kejariwal A, Thomas PD: PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways. Nucleic Acids Res 35 (Database issue):D247-D252, 2007.
45. Morgan-Lappe S, Woods KW, Li Q, Anderson MG, Schurdak ME, Luo Y, et al: RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors. Oncogene 25:1340-1348, 2006.
46. Mori R, Xiong S, Wang Q, Tarabolous C, Shimada H, Panteris E, et al: Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells. Prostate 69:12-23, 2009.
47. Mukherji M, Bell R, Supekova L, Wang Y, Orth AP, Batalov S, et al: Genome-wide functional analysis of human cell-cycle regulators. Proc Natl Acad Sci U S A 103:14819-14824, 2006.
48. Orth AP, Batalov S, Perrone M, Chanda SK: The promise of genomics to identify novel therapeutic targets. Expert Opin Ther Targets 8:587-596, 2004.
49. Oyaizu H, Adachi Y, Okumura T, Okigaki M, Oyaizu N, Taketani S, et al: Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in human lung adenocarcinoma cell line. Oncol Rep 8:825-829, 2001.
50. Parsons DW, Jones S, Zhang X, Lin JCH, Leary RJ, Angenendt P, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812, 2008.
51. Pollack I: Growth factor signaling pathways and receptor tyrosine kinase inhibitors, in Newton HB (ed): Handbook of Brain Tumor Chemotherapy. Philadelphia: Elsevier, 2006, pp 155-172.
52. Ramadan N, Flockhart I, Booker M, Perrimon N, Mathey-Prevot B: Design and implementation of high-throughput RNAi screens in cultured Drosophila cells. Nat Protoc 2:2245-2264, 2007.
53. Raychaudhuri B, Han Y, Lu T, Vogelbaum MA: Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype. J Neurooncol 85:39-47, 2007.
54. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al: Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9:166-180, 2007.
55. Robinson R: RNAi therapeutics: how likely, how soon? PLoS Biology 2(1):e28, 2004.
56. Russ AP, Lampel S: The druggable genome: an update. Drug Discov Today 10:1607-1610, 2005.
57. Sachse C, Echeverri CJ: Oncology studies using siRNA libraries: the dawn of RNAi-based genomics. Oncogene 23:8384-8391, 2004.
58. Sathornsumetee S, Reardon DA: Targeting multiple kinases in glioblastoma multiforme. Expert Opin Investig Drugs 18:277-292, 2009.
59. Schultz N, Lopez E, Saleh-Gohari N, Helleday T: Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res 31:4959-4964, 2003.
60. Sepp KJ, Hong P, Lizarraga SB, Liu JS, Mejia LA, Walsh CA, et al: Identification of neural outgrowth genes using genomewide RNAi. PLoS Genet 4:e1000111, 2008.
61. Short SMC, Mayes C, Woodcock M, Johns H, Joiner MC: Low dose hypersensitivity in the T98G human glioblastoma cell line. Int J Radiat Biol 75:847-855, 1999.
62. Stein GH: T98G: an anchorage-independent human tumor cell line that exhibits stationary phase G1 arrest in vitro. J Cell Physiol 99:43-54, 1979.
63. Meier S, Gehring C: A guide to the integrated application of on-line data mining tools for the inference of gene functions at the systems level. Biotechnol J 3:1375-1387, 2008.
64. Sudheerkumar P, Shiras A, Das G, Jagtap JC, Prasad V, Shastry P: Independent activation of Akt and NF-kappaB pathways and their role in resistance to TNF-alpha mediated cytotoxicity in gliomas. Mol Carcinog 47:126-136, 2008.
65. Tai AW, Benita Y, Peng LF, Kim SS, Sakamoto N, Xavier RJ, et al: A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 5: 298-307, 2009.
66. Tang D, Kehrer J: Carcinogenesis: balance between apoptosis and survival pathways, in Srivastava R (ed): Apoptosis, Cell Signaling, and Human Diseases: Molecular Mechanisms. Totowa NJ: Humana Press, 2007, Vol 1.
67. Tang W, Dodge M, Gundapaneni D, Michnoff C, Roth M, Lum L: A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. Proc Natl Acad Sci U S A 105:9697-9702, 2008.
68. Thaker NG, Zhang F, McDonald PR, Shun TY, Lewen MD, Pollack IF, et al: Identification of Survival Genes in Human Glioblastoma Cells Using siRNA Screening. Mol Pharmacol [epub ahead of print], 2009.
69. Tu Z, Argmann C, Wong KK, Mitnaul LJ, Edwards S, Sach IC, et al: Integrating siRNA and protein-protein interaction data to identify an expanded insulin signaling network. Genome Res 19:1057-1067, 2009.
70. Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, et al: A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 27:1368-1377, 2008.
71. Valster A, Tran NL, Nakada M, Berens ME, Chan AY, Symons M: Cell migration and invasion assays. Methods 37:208-215, 2005.
72. Weiss GJ, Kingsley C: Pathway targets to explore in the treatment of non-small cell lung cancer. Journal of Thoracic Oncology 3:1342-1352, 2008.
73. Weller MRJ, Rieger J, Grimmel C, Van Meir EG, De Tribolet N, Krajewski S, et al: Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int J Cancer 79:640-644, 1998.
74. Westbrook TF, Martin ES, Schlabach MR, Leng Y, Liang AC, Feng B, et al: A genetic screen for candidate tumor suppressors identifies REST. Cell 121:837-848, 2005.
75. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, et al: Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446:815-819, 2007.
76. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67-73, 1999.
77. Zhang Z, Jiang G, Yang F, Wang J: Knockdown of mutant Kras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells. Cancer Biol Ther 5:1481-1486, 2006.